Statistical issues in the use of dynamic allocation methods for balancing baseline covariates

por Pond, G R
Publicado 2011

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy

por Vardy, J, Chiew, K S, Galica, J, Pond, G R, Tannock, I F
Publicado 2006

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer

por Hilton, J.F., Clemons, M., Pond, G., Zhao, H., Mazzarello, S., Vandermeer, L., Addison, C.L.
Publicado 2017

P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers

por Beltran-Bless, A.-A., Larocque, G., Arnaout, A., Caudrelier, J.-M., Vandermeer, L., Pond, G., Clemons, M.
Publicado 2023

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK

por Storozhuk, Y, Hopmans, S N, Sanli, T, Barron, C, Tsiani, E, Cutz, J-C, Pond, G, Wright, J, Singh, G, Tsakiridis, T
Publicado 2013

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer

por Addison, C.L., Simos, D., Wang, Z., Pond, G., Smith, S., Robertson, S., Mazzarello, S., Singh, G., Vandermeer, L., Fernandes, R., Iyengar, A., Verma, S., Clemons, M.
Publicado 2016

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

por Townsley, C A, Major, P, Siu, L L, Dancey, J, Chen, E, Pond, G R, Nicklee, T, Ho, J, Hedley, D, Tsao, M, Moore, M J, Oza, A M
Publicado 2006

P279 A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?

por Beltran-Bless, A.-A., Larocque, G., Brackstone, M., Arnaout, A., Caudrelier, J.-M., Boone, D., Fallah, P., Ng, T., Cross, P., Alqahtani, N., Hilton, J., Vandermeer, L., Pond, G., Clemons, M.
Publicado 2023

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

por Duran, I, Kortmansky, J, Singh, D, Hirte, H, Kocha, W, Goss, G, Le, L, Oza, A, Nicklee, T, Ho, J, Birle, D, Pond, G R, Arboine, D, Dancey, J, Aviel-Ronen, S, Tsao, M-S, Hedley, D, Siu, L L
Publicado 2006